CHICMAX (02145) announced its annual results for the period ending December 31, 2025. The group achieved revenue of RMB 9.178 billion, representing a year-on-year increase of 35.12%. Profit attributable to owners of the parent company was RMB 1.103 billion, up 41.14% compared to the previous year. Earnings per share were RMB 2.77, and the board recommended a final dividend of RMB 0.75 per share.
The growth in the group's revenue, which rose 35.1% from RMB 6.793 billion in 2024 to RMB 9.178 billion in 2025, was driven by the successful multi-brand and multi-category strategy. This included sustained revenue growth from the scientific anti-aging skincare brand Kans, a significant year-on-year increase in revenue from the Chinese infant and child efficacy skincare brand newpage one page, and breakthrough growth from the sensitive skin-focused efficacy skincare brand Anminyou.
Revenue attributable to Kans increased by 31.6%, from RMB 5.591 billion in 2024 to RMB 7.36 billion in 2025. This was mainly due to the brand's successful expansion into men's grooming, hair care, personal care, and color cosmetics, alongside its core skincare focus, leading to rapid revenue growth across all channels.
The company began its independent research and development activities in 2003 and has consistently adhered to in-house product development. Its dual R&D centers are dedicated to building a robust platform for advanced fundamental research and product development. These efforts are closely aligned with consumer needs, focusing on product development and the application of new technologies to adapt to the evolving market.
The company is committed to attracting and nurturing talent, having established a strong team with extensive R&D experience. It maintains substantial and effective investment in research and development. In 2025 and 2024, the company incurred R&D expenses of RMB 225 million and RMB 180 million, respectively, representing a 24.9% year-on-year increase in 2025.
Comments